MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.990
+0.150
+5.28%
Opening 10:13 01/19 EST
OPEN
3.050
PREV CLOSE
2.840
HIGH
3.050
LOW
2.910
VOLUME
140.57K
TURNOVER
--
52 WEEK HIGH
4.459
52 WEEK LOW
0.7200
MARKET CAP
336.44M
P/E (TTM)
-5.7544
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
What Type Of Shareholders Own The Most Number of MEI Pharma, Inc. (NASDAQ:MEIP) Shares?
If you want to know who really controls MEI Pharma, Inc. ( NASDAQ:MEIP ), then you'll have to look at the makeup of its...
Simply Wall St. · 5d ago
MEI Pharma expands early-stage zandelisib trial in specific blood cancer cohorts
MEI Pharma ([[MEIP]] +6.4%) has announced that the Phase 1b trial arm exploring zandelisib in combination with BeiGene's Brukinsa (zanubrutinib) has completed the safety evaluation stage in patients with B-cell
Seekingalpha · 01/04 20:24
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
- Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies - - MEI provides clinical pipeline outlook for 2021 - -
Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies - - MEI provides clinical pipeline outlook for 2021 - - · 01/04 12:12
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm exploring zandelisib, an investigational sele...
PR Newswire · 01/04 12:00
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update
PR Newswire · 01/04 12:00
Is MEIP A Good Stock To Buy Now?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in re...
Insider Monkey · 12/16/2020 01:40
Growth Investors: Industry Analysts Just Upgraded Their MEI Pharma, Inc. (NASDAQ:MEIP) Revenue Forecasts By 25%
Simply Wall St. · 11/15/2020 14:20
Growth Investors: Industry Analysts Just Upgraded Their MEI Pharma, Inc. (NASDAQ:MEIP) Revenue Forecasts By 25%
Shareholders in MEI Pharma, Inc. (NASDAQ:MEIP) may be thrilled to learn that the analysts have just delivered a major...
Simply Wall St. · 11/15/2020 14:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MEIP. Analyze the recent business situations of MEI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MEIP stock price target is 9.60 with a high estimate of 13.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 144
Institutional Holdings: 78.13M
% Owned: 69.43%
Shares Outstanding: 112.52M
TypeInstitutionsShares
Increased
30
3.69M
New
35
2.35M
Decreased
37
2.83M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
+0.94%
Key Executives
Non-Executive Chairman/Independent Director
Christine White
Chief Executive Officer/President/Director
Daniel Gold
Chief Financial Officer/Secretary
Brian Drazba
Chief Operating Officer/General Counsel
David Urso
Senior Vice President/Director of Marketing
Brian Powl
Other
Robert Mass
Independent Director
Charles Baltic
Independent Director
Kevan Clemens
Independent Director
Cheryl Cohen
Independent Director
Frederick Driscoll
Independent Director
Nicholas Glover
Independent Director
Tamar Howson
Independent Director
Thomas Reynolds
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MEIP
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.